ライフサイエンスコーパス: portal

1 interaction between the azide group and the portal.

2 after the assembly of adaptor protein to the portal.

3 the web-based BankIt or the NCBI Submission Portal.

4 The survey was conducted through an online portal.

5 g a common tool and entered into a Web-based portal.

6 and visualization features through a single portal.

7 sociation, and the City of Toronto Open Data Portal.

8 indicating an induced fit on binding to the portal.

9 orm and through a controlled-access internet portal.

10 lopedia and the Cancer Therapeutics Response Portal.

11 ons at the second ureidyl C horizontal lineO portal.

12 based support, social platforms, and patient portals.

13 ...O horizontal lineC close contacts at both portals.

14 omponents are at slightly lower resolutions: portal (9.2 A), hub (8.5 A), tailspike (10.9 A), and nee

15 called the 'portal vertex' and consists of a portal, a DNA packaging ATPase and other components.

16 Together, we have built the TB Portals, a repository of socioeconomic/geographic, clini

17 is not cleared by the liver, independent of portal ammonia concentrations </=2 mmol/L.

18 An electronic anonymized patient portal analysis using radiographic reports and admission

19 e 2.45 mL/mL (arterial input) or 2.66 mL/mL (portal and arterial input).

20 ed information extracted from the LINCS Data Portal and ChEMBL.

21 improves engraftment most effectively in the portal and DL subcutaneous sites.

22 early apoptosis-mediated islet death within portal and extrahepatic portal sites in mice.

23 ct data is presented through the HipSci data portal and is downloadable from the associated FTP site

24 xpression omnibus (GEO), such as the GEO web portal and related applications, are optimized to reanal

25 ated through echographic measurements, while portal and systemic pressures were measured through poly

26 dical research community, spread across many portals and represented in various formats.

27 nal Clinical Trials Registry Platform Search Portal, and clinicaltrials.gov The date of the last sear

28 nal Clinical Trials Registry Platform Search Portal, and clinicaltrials.gov The date of the last sear

29 ens utilise this natural opening as an entry portal, and thus have an increasingly complex relationsh

30 Portosystemic shunting was demonstrated by portal angiography, which disclosed virtually complete p

31 RT: We present imaging findings in a case of portal annular pancreas in a 45-year-old male patient.

32 Portal annular pancreas is a rare and often neglected pa

33 Portal annular pancreas is a rare pancreatic development

34 : We present Galaxy Portal app, an open source interface to the Galaxy syste

35 Biliary ductal cells proliferate from the portal areas of chronically damaged livers, but their si

36 iopsy, which was moderate to severe (<50% of portal areas with bile ducts) in 14 and mild (50%-75%) i

37 vascular structures, wall thickening of some portal arteries, and periductal fibrosis in Fut2(-/-)(hi

38 ular involvement of all hepatic veins (V) or portal bifurcation (P), contiguous extrahepatic tumour (

39 nstantly exposed to gut-derived antigens via portal blood and, as a consequence, they express a uniqu

40 Portal blood flow and renal and splenic resistive indexe

41 both models of cirrhosis without changes in portal blood flow, suggesting a reduction in IHVR.

42 We demonstrate the utility of this portal by presenting results obtained from The Cancer Ge

43 organized and presented in a searchable web-portal called gene-drug Interaction for survival in canc

44 We created a portal called TumorMap to assist in exploration and stat

45 Additionally, the CIIPro portal can identify the most similar compounds based on

46 proceed because of a technical failure with portal cannulation and was discarded.

47 e interaction between organic azides and the portal carbonyls of cucurbiturils.

48 tor ratchets DNA into the capsid through the portal channel.

49 of gut-derived antigens that arrive through portal circulation at homeostasis and protect these orga

50 The portal circulation has a distinct immunological milieu c

51 the TMA produced is passively absorbed into portal circulation, and hepatic flavin-dependent monooxy

52 l permeability, release of microbes into the portal circulation, and increased serum levels and liver

53 uctose uptake and transport into the hepatic portal circulation.

54 nction with the Cancer Therapeutics Response Portal (CTRP), a dataset with drug-response measurements

55 The TB Portals database and associated projects are continually

56 DynOmics (dynomics.pitt.edu) is a portal developed to leverage rapidly growing structural

57 oietic cell types by the Differentiation Map Portal (DMAP) project.

58 ferentiation and homeostasis of these thymic portal ECs.

59 nd the results are presented as a public web-portal (EDDY-CTRP).

60 The HipSci portal enables researchers to choose the right cell line

61 t and is associated with early activation of portal fibroblasts (PFs) that express Thy-1, fibulin 2,

62 letion results in a significant reduction of portal fibrosis and portal hypertension as well as of li

63 Portal fibrosis, bridging, parenchymal nodules, portal i

64 tter understanding of reciprocal dynamics of portal flow and regeneration between the graft and nativ

65 as to study hepatic blood flow and effect of portal flow modulation on graft outcomes in the setting

66 st the need for a study using a prespecified portal flow modulation protocol with defined indications

67 A total of 57 portal flow modulations were performed on 52 subjects.

68 terial fraction, and arterial flow but lower portal flow, distribution volume, and mean transit time

69 inconsistent effects on hepatic arterial and portal flow.

70 mall-molecules profiled, and developed a web portal for browsing and searching predictive small-molec

71 The EMDataBank project provides a unified portal for deposition, retrieval and analysis of 3DEM de

72 and visualization, concise gene summaries, a portal for external resources, video tutorials and the F

73 d reinterpretation of sieve effects and as a portal for organizing and sharing the viral sequence dat

74 A new data portal for sharing such maps is discussed.

75 ant data for every strain, and a GWA mapping portal for studying natural variation in C. elegans Addi

76 ve contraction along the anterior intestinal portal generates tension to elongate the foregut and hea

77 arterial blood glucose 146 +/- 2 mg/dL) with portal GLC infusion.

78 l helix-loop observed in the Sf6-gp7 and P22 portal:gp4 complex represents the pre- and postassembly

79 GKRP, and it is activated postprandially by portal hyperglycemia and fructose through dissociation f

80 CLD), the presence of clinically significant portal hypertension (CSPH) and varices needing treatment

81 ssociated cirrhosis and clinical significant portal hypertension (CSPH, hepatic venous pressure gradi

82 rices (EVs) or having clinically significant portal hypertension (for presurgical risk stratification

83 nrolled patients with compensated cirrhosis, portal hypertension (hepatic venous pressure gradient [H

84 ss vary differently with respect to cause of portal hypertension (ie, congestion- or cirrhosis-induce

85 ed with progressively developed fibrosis and portal hypertension (mean stiffness at 80 Hz and 48-week

86 resistance (IHVR) is the primary factor for portal hypertension (PH) development.

87 Portal hypertension (PH) is a major cause of morbidity a

88 rization, and developed less-severe forms of portal hypertension after portal vein ligation.

89 nts, ductular cell expansion correlated with portal hypertension and collagen expression.

90 oteins CPEB1 and CPEB4 during development of portal hypertension and liver disease.

91 Progressive liver fibrosis leads to portal hypertension and liver failure; however, the mech

92 The aim of this study is to evaluate portal hypertension as an independent risk factor in gen

93 significant reduction of portal fibrosis and portal hypertension as well as of liver cysts.

94 er cirrhosis is complicated by bleeding from portal hypertension but also by portal vein thrombosis (

95 ality Improvement Program (NSQIP) formed the portal hypertension cohort, and were case matched to pat

96 l hemorrhage is a concerning complication of portal hypertension in children, the first bleed appears

97 Data on the impact of portal hypertension in general surgical outcomes has bee

98 t leads to better control of RA secondary to portal hypertension in patients with cirrhosis, compared

99 lications related to liver insufficiency and portal hypertension in patients with heavy alcohol intak

100 rogeneous group of diseases characterized by portal hypertension in the absence of cirrhosis.

101 Idiopathic noncirrhotic portal hypertension is a heterogeneous group of diseases

102 Portal hypertension is associated with a significant mor

103 ght subjects from six kindreds with onset of portal hypertension of indeterminate etiology during inf

104 rts of patients with idiopathic noncirrhotic portal hypertension undergoing TIPS in seven centers bet

105 Liver injury with portal hypertension was established using bile duct liga

106 s induced in rats by bile duct ligation, and portal hypertension was induced by partial portal vein l

107 In patients with idiopathic noncirrhotic portal hypertension who have normal kidney function or d

108 cutive patients with severe complications of portal hypertension who received placement of TIPS from

109 ephalopathy, esophageal varices, ascites, or portal hypertension) or liver transplant were estimated

110 scarring from any cause leads to cirrhosis, portal hypertension, and a progressive decline in renal

111 with hepatic "recompensation," reduction of portal hypertension, and eventually avoidance of liver t

112 parenchyma, leading to hepatic dysfunction, portal hypertension, and hepatomegaly.

113 , FAH(-/-) pigs developed liver fibrosis and portal hypertension, and thus may serve as a large-anima

114 varices, which are most commonly a result of portal hypertension, downhill esophageal varices result

115 early-onset familial idiopathic noncirrhotic portal hypertension, in which Mendelian mutations may ac

116 reased risk attributable to complications of portal hypertension, including variceal rupture.

117 Idiopathic EHPVT, a significant cause of portal hypertension, is surgically corrected by MRB.

118 is and management of idiopathic noncirrhotic portal hypertension, its pathogenesis remains elusive.

119 with preoperative hierarchic interaction of portal hypertension, planned extension of hepatectomy, a

120 oportions of patients in the LVP+A group had portal hypertension-related bleeding (18% vs 0%; P = .01

121 of varices and the incidence and outcome of portal hypertension-related bleeding.

122 l dysfunction in patients with cirrhosis and portal hypertension.

123 liary dysgenesis, portal tract fibrosis, and portal hypertension.

124 patients with alcohol-related cirrhosis and portal hypertension.

125 rt and disclosed a transudate, suggestive of portal hypertension.

126 tic portosystemic shunt (TIPS) for cirrhotic portal hypertension.

127 ellular carcinoma (HCC), without evidence of portal hypertension.

128 odilation, which contributes to the onset of portal hypertension.

129 rhosis and liver failure but not in isolated portal hypertension.

130 atic inflammation, fibrosis, congestion, and portal hypertension.

131 eries of rats and mice with cirrhosis or/and portal hypertension.

132 lent option to treat severe complications of portal hypertension.

133 lting in functional Budd-Chiari syndrome and portal hypertension.

134 overweight/obese patients with cirrhosis and portal hypertension.

135 but did not change hemodynamic parameters in portal hypertensive rats.

136 esources have been added to the RCSB PDB web portal in support of a 'Structural View of Biology.' Rec

137 CRAVAT can be run on a public web portal, in the cloud, or downloaded for local use, and i

138 Portal infiltrates persisted at 3 years but were charact

139 s (taurocholate), lobular (glycocholate) and portal inflammation (taurolithocholate), and hepatocyte

140 NASH), histologically defined by lobular and portal inflammation, and accompanied by marked oxidative

141 tal fibrosis, bridging, parenchymal nodules, portal inflammation, hepatocellular swelling, steatosis,

142 patitis Clinical Research Network system for portal inflammation.

143 Portal inflow modification (splenic artery ligation, hem

144 , insulin sensitivity and clearance, and the portal insulin:glucagon ratio.The addition of lactisole

145 -pH route into epithelial cells, the primary portal into the host.

146 At the core of the portal is a newly developed server, ENM 1.0, which permi

147 delling studies indicate the structure of PC-portal is incompatible with DNA coaxially spooled around

148 However, a protein that functions as a portal is not yet identified in AdVs.

149 This dataset along with a web portal is provided to the community to assist in the dis

150 While the important feature of this public portal is the ability for the users to build maps from t

151 at of the widespread class of outer-membrane portals known as secretins.

152 ponsive element-binding protein and featured portal/lobular inflammation along with total, whole-body

153 ocellular swelling, steatosis, dilatation of portal lymphatics, and periductal fibrosis did not show

154 ere investigated in Genomic Data Common data portal miRNA-Seq dataset and The Cancer Genome Atlas (TC

155 kaging machine consists of three components: portal, motor (large terminase; TerL) and regulator (sma

156 e N-terminal domain and within the substrate portal nearly 30 A away.

157 Looking for and treating the portal of entry (POE) of infective endocarditis (IE) is

158 vironmental substances and represent a major portal of entry for microorganisms.

159 by improving immune defenses at the mucosal portal of entry.

160 serving as a likely permissive reservoir and portal of fetal transmission with risk of latent microce

161 attribute to the larger size of the carbonyl portals of CB[8]; this suggests routes to develop CB[8]

162 ontribution of fibroblastic stromal cells as portals of entry into the CNS was only recently uncovere

163 or preventing HIV-1 infection at the mucosal portals of infection.

164 The natural portals of virus entry are the mucosal surfaces and the

165 P=0.04), access their CHD risk via a patient portal (OR, 2.99 [CI, 1.35-7.04]; P=0.01), and discuss t

166 ed or absent contrast enhancement during the portal phase.

167 Remarkably, while the distance between the portal plane and most atoms at the guest end groups incr

168 atoms maintain a constant distance from the portal plane in all homologues, pointing at a strong att

169 The data portal presents a summary matrix of the HipSci cell line

170 RVXB significantly decreased portal pressure (PP) in both models of cirrhosis without

171 Monitoring the hemodynamic response of portal pressure (PP) to drug therapy accurately stratifi

172 BACKGROUND & AIMS: A reduction in portal pressure gradient (PPG) to <12 mm Hg after placem

173 The portal pressure gradient was determined based on HVPG at

174 Modulation lowered portal pressure in 68% of subjects with inconsistent eff

175 derate exercise were safe and reduced BW and portal pressure in overweight/obese patients with cirrho

176 Statins decrease portal pressure in patients with cirrhosis and increase

177 s with cirrhosis, and if weight loss reduces portal pressure in this setting, is unknown.

178 Mean portal pressure was dropped from 33.08 +/- 1.38 mmHg pre

179 Necroinflammation, fibrosis, and portal pressure were either histologically scored or bio

180 on by IFX was associated with a reduction in portal pressure.

181 nsation in cirrhosis, possibly by increasing portal pressure.

182 is extent (hydroxyproline concentration) and portal pressure.

183 The TB Portals program is an international consortium of physic

184 f the major head protein, 12 subunits of the portal protein and 120 subunits of the decoration protei

185 C-terminal arm, which may interact with the portal protein during motor assembly, as predicted for s

186 ere, we provide structural evidence that the portal protein of the bacteriophage P22 exists in two di

187 ly through binding to the -domain, while the portal protein regulates assembly into the correct T=13

188 is a tail adaptor protein that connects the portal protein to the other tail proteins.

189 on of the genome DNA within the channel, the portal protein would become a Brownian motor, which adop

190 in turn, affect the channel activity of the portal protein, GP10, embedded in the semipermeable caps

191 d scaffolding protein and by one dodecameric portal protein.

192 ults suggest that E4 34K is the putative AdV portal protein.

193 kaging' is a DNA-dependent symmetrization of portal protein.

194 h as the alpha-helical barrel domains of P22 portal proteins and T7 proteins that form tail tube exte

195 nd compared them with the clip region of the portal proteins of bacteriophages phi29, SPP1 and T4.

196 hat of single subunits of Phi29, SPP1 and T4 portal proteins revealed remarkable similarity.

197 similarity with the clip region of the known portal proteins.

198 open-source, curated plant pathway database portal, provided as part of the Gramene project.

199 The Galaxy Portal provides convenient and efficient monitoring of j

200 In total, our portal provides fast access to genetic variants observed

201 The CIIPro portal provides new powerful assessment capabilities to

202 omeCentral remains as the common data access portal, providing the ability to search for data sets in

203 tutional review board protocol 2 hours after portal reperfusion, followed by Western blot analyses.

204 The site of EHD affected survival, with portal, retroperitoneal nodes and multiple sites associa

205 The site of EHD affected survival, with portal, retroperitoneal nodes and multiple sites associa

206 d islet death within portal and extrahepatic portal sites in mice.

207 for the identification of gas in the hepatic portal system in children.

208 ct portography and percutaneous transhepatic portal techniques to increase the rate of success.

209 We have also introduced a new data portal that increases discoverability of our data-previo

210 nd a symmetric ring in the mature virion (MV-portal) that has negligible affinity for the packaging m

211 an asymmetric assembly in the procapsid (PC-portal) that is competent for high affinity binding to t

212 ximately 0.32 A above the C horizontal lineO portal; the observed 0.80 A spacing observed for CB[7].D

213 promotes a breach of BM vascular sinusoidal portals, thereby augmenting HSPC trafficking to the circ

214 hat enables its integration into third-party portals, thus providing 'Search as a Service' capabiliti

215 We develop a web portal to serve these signatures for query, download and

216 exploits the HER3 cell surface protein as a portal to sneak therapeutics into tumor cells by mimicki

217 tracking system, screen data repository, and portal to the community.

218 ce for biomedical applications and open up a portal to the next generation of multi-functional electr

219 Patient and care partner access to online portal to view health information, participate in the ca

220 R in PBC livers (particularly in the hepatic portal tracks) support a disease mechanism in which the

221 uding liver-specific inflammation focused on portal tract areas, increased number and activation stat

222 y, and in the liver with biliary dysgenesis, portal tract fibrosis, and portal hypertension.

223 Morphometric measurements of portal tract structures were performed and correlated wi

224 rosis (>6 weeks) after DR migration from the portal tracts to the centrilobular site of injury, in as

225 tected from the blood vessels and around the portal tracts.

226 c lobule or histologic nodular growth in the portal triad that effaced adjacent hepatic parenchyma.

227 double-heterozygous mice show well-developed portal triads around most portal veins, with no elevatio

228 Embolization was performed in the portal trunk of C57BL6 adult mice with polyester microsp

229 r results were found across types of patient portal use (communicating by email, viewing laboratory t

230 ortal shunting vessels, increased numbers of portal vascular structures, wall thickening of some port

231 cially on thrombotic total occlusion of main portal vein (MPV).

232 nderwent 2D phase-contrast MR imaging of the portal vein (PV) and infrahepatic and suprahepatic infer

233 arginal islet dose (150 islets), or into the portal vein (PV) at a full dose (500 islets).

234 or mesenteric vein (SMV), splenic vein (SV), portal vein (PV), and the TIPS.

235 Portal vein and bile duct area index were significantly

236 ernative porto-caval shunt between the right portal vein and inferior vena cava detected on postnatal

237 A portal vein area index <0.08 had a lower chance of succe

238 model perfused with autologous blood via the portal vein at three flow rates (60, 80, 100 mL/min per

239 sion Unlike monopolar RF ablation, change in portal vein flow rates does not have a statistically sig

240 rpose To investigate the effect of change in portal vein flow rates on the size and shape of ablation

241 pectrometry with (ii) direct sampling of the portal vein following an intravenous glucose/arginine ch

242 Portal vein hypertension (PVH) in liver cirrhosis compli

243 the setting of hepatocellular carcinoma with portal vein invasion, and for radiation segmentectomy.

244 ation after extended partial hepatectomy and portal vein ligation for multiple bilobar CRLM were appl

245 ation after extended partial hepatectomy and portal vein ligation for multiple bilobar CRLM were appl

246 djustment in Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) occu

247 Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), a 2

248 r regeneration after partial hepatectomy and portal vein ligation, and increased the expression of ce

249 r regeneration after partial hepatectomy and portal vein ligation, and increased the expression of ce

250 d portal hypertension was induced by partial portal vein ligation.

251 ss-severe forms of portal hypertension after portal vein ligation.

252 vasion into the extra-hepatic portion of the portal vein or the development of distant metastases ren

253 creased clot formation rate, associated with portal vein platelet aggregates and reductions in protei

254 were mainly rejected for comorbidity (19%), portal vein thrombosis (16%), previous surgery (9%), obe

255 s of the liver in children with extrahepatic portal vein thrombosis (EHPVT), with surgical outcome af

256 Portal vein thrombosis (PVT) is common in patients with

257 ed-stage hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) treated with (90)Y radioemb

258 leeding from portal hypertension but also by portal vein thrombosis (PVT).

259 Portal vein thrombosis at listing was not associated wit

260 Portal vein thrombosis at LT is associated with early (9

261 Three (2.9%) grafts were lost due to portal vein thrombosis.

262 ing for age, sex, treatment, tumor size, and portal vein thrombosis.

263 eport that TMED3 was up-regulated in HCC and portal vein tumor thrombus.

264 venous system and subsequently develop into portal vein tumour thrombosis (PVTT).

265 , 17 (17.3%) had cavernous transformation of portal vein, and 3 (3.1%) had post-transplant thrombosis

266 d texture mapping of tumors, hepatic artery, portal vein, and the hepatic veins was developed.

267 from the gastrointestinal tract through the portal vein, and thereby is exposed continuously to diet

268 x 2 cm x 2.1 cm in size with abutment of the portal vein-superior mesenteric vein confluence for less

269 that occurs when islets are infused into the portal vein.

270 Results Occlusion was identified in 39.7% of portal veins (29 of 73), 15.0% of hepatic veins (six of

271 f 21 patients with target tumors adjacent to portal veins developed mild to moderate cholestasis 2-6

272 resistant to vessel occlusion compared with portal veins, and only arterial patency within an ablati

273 immediately adjacent to major hepatic veins, portal veins, or both; thus, they were not considered su

274 covered extrinsic compression of hepatic and portal veins, resulting in functional Budd-Chiari syndro

275 how well-developed portal triads around most portal veins, with no elevation of serum bilirubin.

276 Approximately 200 had portal venous and arterial pressure and flow measurement

277 ermined in arterial, hepatic venous (HV) and portal venous blood (PV).

278 Hepatic portal venous gas (HPVG) is a rare imaging finding in ch

279 or more of pneumoperitoneum, fixed loop, and portal venous gas were present, and 1 point was assigned

280 ase states, minimally invasive transcatheter portal venous interventions have been developed to impro

281 dual-energy CT and arterial perfusion (AP), portal venous perfusion, and total perfusion (TP) from p

282 LSN scores from portal venous phase contrast-enhanced thick-section CT i

283 uded imaging during the hepatic arterial and portal venous phases in one scan.

284 Portal venous pressure and intrahepatic endothelial dysf

285 was associated with increased postoperative portal venous pressure and von Willebrand factor antigen

286 ostpreservation, as well as 30 minutes after portal venous reperfusion and hepatic arterial reperfusi

287 in ATP:ADP, ATP:AMP and energy charge after portal venous reperfusion, respectively.

288 lular carcinoma (HCC) cells often invade the portal venous system and subsequently develop into porta

289 on (PVH) in liver cirrhosis complicated with portal venous thrombosis (PVT) has been mainly treated w

290 r detection of arterial hypervascularity and portal venous washout.

291 genome, growth of a tubular structure from a portal vertex and release of the genome.

292 ex assembles at a special vertex called the 'portal vertex' and consists of a portal, a DNA packaging

293 atible with DNA coaxially spooled around the portal vertex, suggesting that newly packaged DNA trigge

294 ter closure of the umbilical inlet at birth, portal vessels undergo a transition from Neuropilin-1(+)

295 G2(+) cells and emigration of HSCs away from portal vessels.

296 Through this portal, we make available protocols, online tools, and o

297 To identify the AdV portal, we performed secondary structure analysis on a s

298 icipants from the clinic and from the online portal were significantly different in age (mean [SD] ag

299 Chemical In vitro-In vivo Profiling (CIIPro) portal, which can automatically extract in vitro biologi

300 h that of the P22 homolog complexed with the portal, which is achieved by repositioning of two consec

301 Randomisation was done through a web portal, with participants, investigators, and others inv